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5-fluorouracil treatm ent arm, are comparable to what we
observed on the bolus arm of our study.
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Sensitivity of Frozen Section 
Examination of Peivic Lymph Nodes 
for Metastatic Prostate Carcinoma
I read with particular interest the article by Davis1 about the sensitivity of frozen-section examination of pelvic 
lymph nodes for metastatic carcinoma. The section in 
which the results of frozen section are compared with 
imaging techniques found in the Medical Literature Anal­
ysis and Retrieval System (MEDLARS) literature research 
deserves comment.
The author’s conclusion that " . . .  frozen section di­
agnosis of pelvic lymph nodes . . . .  is more sensitive for 
the diagnosis of prostate carcinoma in pelvic lymph 
nodes than  is MRI because more than half of the metasta- 
ses are smaller than the 1-cm resolution limit of the MRI,” 
may be misleading and is not correct.
The upper limit of the spatial resolution of magnetic 
resonance imaging (MRI) and computed tomography 
(CT) is m uch smaller than 1 cm. It depends on many 
factors, such as field of view, matrix size, slice thickness, 
image quality (signal-to-noise ratio, motion artifacts) and 
contrast between the object and surrounding structures. 
Using a three-dimensional imaging technique, we 
achieved an in-plane resolution of 1.3 mm X 1 mm and 
were able to visualize lymph nodes with a diameter of
4 mm.2
Also, the literature search on imaging techniques is 
incomplete. The reviewed number of articles on CT and 
MRI is far too low; for example, the review does not in­
clude the article by Rifkin et al.,3 which includes more 
patients (185) investigated with MRI than the compilated
data of the articles cited by the author. In this series, the 
sensitivity was only 4%.
In general, it is believed that MRI is equal to CT for 
lymph node imaging. The advantage of CT over MRI is 
that fine-nee die aspiration of a lymph node mass may be 
more easy to perform. In contrast to lymphangiography, 
in which métastasés are visible as filling defects of 4 mm 
or more in diameter,4 MRI and  CT do not allow direct 
visualization of lymph node métastasés. The main criteria 
to assess the presence of lym ph node métastasés is the 
axial diameter of the lymph node. Perhaps the author con­
fused “resolution lim it'’ with w hat is considered as the 
upper limit of a norm al sized lym ph node. However, crite­
ria for positive lymph nodes are arbitrary. In the cited 
articles, the upper limit of norm al varies from 1 cm 5,6 to
1.5 cm.7,8 There is a general tendency to lower the upper 
limit of normal. Recently, Vinnicombe et al.,9 who found 
that only 2% of norm al lymph nodes have a maximum 
short axis diameter of larger than 1 cm, suggested that 
the sensitivity of CT in depicting lymph nodes may be 
improved by adopting lower limits of normal. These may 
become 7 mm for internal iliac, 8 m m  for obturator, 9 mm 
for com m on iliac, and  10 m m  for external iliac lymph 
nodes. Using a three-dimensional imaging technique, we 
could add the shape of the lymph node in the judgment; 
round nodes with a diameter of 8 m m  and an index of 0.8 
(shortest axial diam eter divided by the long axis) or less 
were considered abnormal. W ith these criterion, the fig­
ures for sensitivity, specificity, and accuracy were 58%, 
96%, and 92% in 62 patients (data presented at the  81st 
Annual Meeting of the Radiologic Society of North 
America, Nov-Dee, 1995). Van Poppel et al.10 consider even 
lymph nodes of 6 m m  in diam eter on CT to be positive. 
Calculated figures for sensitivity, specificity, and accuracy 
were 77.8%, 96.6%, and 93.7%, respectively. W hen fine- 
needi e aspiration biopsy was performed to evaluate sus­
pected nodes, the calculated figures were 77.8%, 100%, 
and 96.5%, respectively. These figures are unique and may 
be not representative for imaging in general.
However, the argum ent that frozen section is more 
sensitive than CT or MRI does no t implicate that there is 
no place for imaging as is suggested in the article by 
Davis.1 Lymph node m étastasés detected by imaging will 
considerably save financial costs, morbidity, hospital 
stay, and patient discomfort. However, only 10% of pa­
tients who are candidates for surgical cure have m eta­
static lymph node disease.11,12 Therefore, cross-sectional 
imaging is not indicated for all patients. It should be re­
stricted for patients who are at high risk for having lymph 
node métastasés depending on prostate specific antigen, 
stage, and the Gleason biopsy score. Wolf et al.13 have 
estimated that w hen  the sensitivity of imaging was 36% 
(baseline derived from literature), imaging would be ben­
eficial w hen  the probability of m étastasés was 32% and
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when suspected lymph nodes were confirmed by fine- 
needle aspiration biopsy.
In conclusion, imaging is still of value in a selected 
group of patients who are at high risk for lymph node 
métastasés to prevent them  from an unnecessaiy opera­
tion. In my opinion, in this group of patients, the upper 
limit of normal should be less than  1 cm.
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Author Reply
I thank Dr. Jager for his comments. He is correct regard­ing my confusion between the spatial resolution limit 
of the imaging technique and the criteria for metastasis 
(the axial diameter of the lymph node). The purpose of 
my study was to assess the  diagnostic efficiency of fro­
zen section and then com pare the results with the only 
other modality available for the direct assessm ent of 
lymph node métastasés prior to p ro s ta tec to m y -im ­
aging.
I did miss the 1990 article by Rifkin et al.,1 which 
indicates that magnetic resonance imaging and com­
puted tomography had high specificity (96%) but very low 
sensitivity (4%) for the diagnosis of lymph node m étasta­
sés “because neither technique has the ability to identify 
microscopic spread of disease."1 In 1995, using either a 
4-mm resolution limit for lymphangiography or a 6-mm 
limit for computed tomography, the best imaging tech­
niques cited by Dr. Jager, 18 of 39 or 22 of 39 patients in 
my series2 still would not have been detected due to the 
microscopic size of their métastasés below these respec­
tive resolution limits. Accepting Dr. Jager's criticism, I 
would change the conclusion of the paper to “Frozen 
section analysis is more sensitive for the diagnosis of 
prostate carcinoma in pelvic lymph nodes than are im­
aging techniques because 46% of the métastasés in our 
series are smaller than the lowest (4 mm) resolution limit 
of the imaging techniques to be reported by Barentsz et 
a l / '2
Imaging is of value in identifying patients who are at 
high risk for lymph node métastasés to prevent them from 
an unnecessaiy operation.3 Regardless of imaging tech­
nique or user, with an upper limit of normal lower than 
1 cm, half of our patients with métastasés would still be 
missed and we are therefore unable to identify them in 
advance of lymphadenectomy.
The rapid changes taking place in both the diagnosis 
and treatment of prostate cancer are reflected in editori­
als and articles concerned with prostate specific antigen 
(PSA), biopsy grade, and treatment variables in the litera­
ture3-0 concurrent with the submission and publication 
of my paper. Imagers face the same dilemma as surgeons; 
how to select patients who will benefit by use of a proce­
dure. Strategies for detecting lymph node métastasés,7,(1 
including imaging with or without fine-needle aspiration 
of “positive” lymph nodes and two-stage (open or lapara- 
scopic) lymphadenectomy, attempt to preselect patients 
at risk for lymph node métastasés by means of PSA, bi­
opsy grade, and clinical staging.
Can current clinical or laboratory parameters preselect 
patients who are at risk for lymph node métastasés? Using 
PSA levels and biopsy grade, we have been unable, retro­
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spectively, to differentiate false-negative frozen-section pa­
tients (microscopic lymph node disease) from tine positive 
patients (unpublished data). Only at the extremes of PSA 
and grade can we predict lymph node metastases with 
greater efficiency than by frozen section and, for the major­
ity of our patients, there is no relationship between PSA 
and biopsy grade, and size of the metastasis. Metastasis 
does not necessarily result in lymph node enlargement.
As prostate cancer is diagnosed "earlier,” I anticipate 
tliat a greater proportion of metastases will be occult,9 for 
the diagnosis of which current routine clinical laboratory 
tests and imaging are inadequate. The application of new 
diagnostic technology (such as polymerase chain reaction 
amplification10 for the detection of currently occult can­
cer cells in the blood stream or tissues obtained with 
minimally or noninvasive techniques with imaging local­
ization) is needed for the accurate and cost-effective stag­
ing and treatm ent of prostate cancer.
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Cost Effectiveness and Outcome 
Assessment of Magnetic Resonance 
Imaging in Diagnosing Cord 
Compression
I read with interest the recent article of Jordan et al., [“Cost Effectiveness and  O utcom e Assessment of Mag­
netic Resonances Imaging in Diagnosing Cord Compres­
sion"] regarding cost-effectiveness of magnetic reso­
nance imaging (MRI) versus m yelography for diagnosing 
malignant epidural spinal cord com pression. I would like 
to raise some issues that m ight influence their m odel
First, the authors do n o t address the issue of how 
m uch of the spinal colum n was im aged in the MRI versus 
the myelography group. W hen m yelography is utilized to 
diagnose cord compression, the standard  of care has been 
a complete myelogram.1 If high-grade block is present, 
this may require a second injection of dye above the level 
of the block. In contrast, the m ean  cost of $2283 for MRI 
patients in Jordan’s study suggests that, on average, fewer 
than two of three spinal segm ents (cervical, thoracic, and 
lumbosacral) were imaged. Therefore, patients receiving 
myelograms were m ore likely to have complete spinal 
imaging. Although m ore expensive, myelography might 
actually result in a better neurologic outcome, since 10% 
to 30% of patients w ith epidural disease at one spinal site 
will have epidural disease at a rem ote site tha t might be 
missed by subtotal spine MRI.2,3,4 Costs in Jordan's two 
groups might have been  quite similar had  each group had 
the entire neuraxis imaged. From the neuro-oncologic 
viewpoint, imaging the entire sp ine is preferable to im­
aging only the segm ent clinically suspected  of harboring 
epidural tumor.
Second, the authors state that the cost of a false positive 
neuroimaging study includes the cost of radiation followed 
by die cost of surgery, implying that standard treatment 
consists of diis combination. They admit that, “radiation 
will not be followed by surgery in all cases." In fact, treat­
m ent for spinal cord compression generally consists of radi­
ation therapy alone. Surgery is sometimes employed as ini­
tial therapy in patients requiring a tissue diagnosis, patients 
with radioresistant tumors, and patients with spinal insta­
bility. Radiation followed by surgery is not standard treat­
ment for spinal cord compression, although this sequence 
of events may occur in patients who deteriorate during radi­
ation, or in patients who eventually relapse following an 
initial response to radiation.
Finally, although spinal cord com pression is indeed 
a neurologic emergency, and although pretreatm ent neu­
rologic status is the m ost im portan t predictor of treat­
m ent outcom e, ¡>,6,7,«,!a j  a m  a w a r e  o f  no data  which sup­
ports the authors’ hypothesis tha t a 16-hour average delay
